The VA Just Started a Phase 3 Psilocybin Trial. The Control Group Gets Psilocybin Too
The Department of Veterans Affairs began enrolling veterans in a phase 3 psilocybin trial on August 3, 2026. The study is called PIVOT. It will treat 240 veterans with treatment-resistant depression across five VA medical centers. The design carries a detail most coverage skipped. There is no placebo group. The control arm receives psilocybin as well, just at a lower dose.
Veteran mental health referrals already reach ketamine clinics in every market. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| What launched | PIVOT, a VA sponsored phase 3 psilocybin trial, began enrolling on August 3, 2026 |
| Size and sites | 240 veterans at five VA medical centers in Alabama, Oregon, Pennsylvania and Washington |
| The unusual design | No placebo arm. Both groups receive COMP360 psilocybin, at different doses in the first session |
| Primary endpoint | Montgomery Asberg Depression Rating Scale score at two weeks |
| Timeline | Primary completion December 2030. Full completion June 2031 |
| Why clinics should care | The trial is a dose response question, and dose determines session length and staffing cost |
What PIVOT Is Actually Testing
PIVOT stands for Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression. The sponsor is the VA Office of Research and Development. It is registered as NCT07226232.
Participants are U.S. military veterans between 18 and 75. They must meet criteria for a major depressive episode. They must score at least 20 on the MADRS depression scale. They must also have failed at least two antidepressants.
Each participant receives two dosing sessions one month apart. Psychological support accompanies both sessions. The primary outcome is the MADRS score two weeks after dosing.
The Control Group Also Receives Psilocybin
The registry lists two arms. One is labeled psilocybin comparator dose. The other is labeled psilocybin intervention dose. Both receive the same drug.
This is the part worth pausing on. PIVOT cannot answer whether psilocybin beats nothing. It can only answer whether a higher dose beats a lower one.
That is a narrower question than the headlines suggest. It is also, arguably, the more useful one at this stage.
Why the Field Moved Away From Placebo
Blinding a psychedelic trial is close to impossible. Participants who receive an active dose usually know it. So do the clinicians sitting with them.
A sugar pill control makes that problem worse, not better. Expectancy then does much of the work the drug is supposed to do. We covered this measurement problem in our look at psychedelic trial methods.
A low dose comparator is the field’s workaround. It gives both groups something to feel. The tradeoff is that a low dose is not inert, so a real effect can be masked.
The Second Session Narrows the Comparison
The registry adds a wrinkle that deserves attention. Participants are randomized to different doses in session one. In session two, every participant receives the same dose.
So the dose comparison effectively covers the first session only. After month one, the two arms converge. Any long term difference between groups gets harder to attribute to dose.
That design choice is defensible on ethical grounds. Nobody wants to leave a depressed veteran on a sub-therapeutic dose for a year. It does limit what the trial can conclude.
The Drug Is COMP360
Both arms receive COMP360. That is Compass Pathways’ synthetic psilocybin formulation.
Worth naming the interest. Compass is a commercial sponsor with a candidate moving toward approval. A federal phase 3 running on its compound is a meaningful validation event for the company. We flagged Compass as a likely acquisition target in our piece on psychedelic takeover candidates.
None of that makes the measurements wrong. Read the measurement and the interpretation separately.
Who Qualifies, and Who Does Not
The exclusion list is long and tells you what the VA is worried about. Lifetime bipolar, schizophrenia or psychotic disorders disqualify a candidate. So does a first-degree relative with that history.
Recent sedative, stimulant or opioid use disorders are excluded. So are severe alcohol and cannabis use disorders. Prior psychedelic use is also disqualifying.
Two more stand out. Recent evidence-based psychotherapy is an exclusion, which is notable given the ongoing argument over what the therapy component actually is. And every participant must have a responsible adult available to drive them home.
The VA Says It Has 20 Psychedelic Trials Running
The announcement included a number worth repeating. The VA says it is involved in 20 active clinical trials of psychedelic therapies.
That reframes the story. This is not an agency testing the water. It is an agency running a research program.
VA Secretary Doug Collins framed the launch around unmet need. “Far too many Veterans are living with mental health conditions that don’t respond to available treatments,” he said. The scale of that demand showed up last year, when RAND estimated nearly 5 million veterans have already tried psychedelics.
Indiana Is Asking a Similar Question
A second dose study started the same month. Indiana University registered NCT07499583, a phase 1/2 trial in 50 veterans and first responders.
It compares 5 mg, 10 mg and 25 mg of psilocybin in a single session. Six weeks of psychotherapy follow. Part of the funding comes from Indiana’s Therapeutic Psilocybin Research Fund, created by the legislature in 2024.
The two trials complement rather than duplicate each other. PIVOT excludes substance use disorder. Indiana requires it. State money has been moving this direction for a while, as with North Carolina’s proposed research fund.
What Ketamine Clinics Should Take From This
Dose response is an operations question disguised as a science question. A 25 mg session and a 5 mg session are not the same product.
The higher dose implies a longer monitoring window. It implies more staff time per patient. It implies a room configured for a full day rather than an afternoon.
If lower doses hold up, the economics of psychedelic services change considerably. That is the same infrastructure calculation we walked through on intravenous psychedelic trials.
What Happens Next
PIVOT is recruiting now at five sites. Primary completion is estimated for December 2030. Final completion is June 2031.
That is a long horizon. Nothing about this trial changes clinical practice in 2026 or 2027.
What it does change is the direction of federal evidence. A VA phase 3 is the strongest institutional signal psychedelic therapy has received. Smaller veteran studies have pointed the same way, including the 12-veteran PTSD trial we covered in July.
This article is for informational purposes and is not medical advice. Psilocybin remains a Schedule I substance under federal law. Veterans interested in trial participation should speak with their VA care team.
